Immunological evaluation and prediction of the effectiveness of interferon therapy for the Japanese multiple sclerosis patients
| Project/Area Number |
19790622
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Neurology
|
|---|
| Research Institution | Tokyo Metropolitan Organization for Medical Research |
|---|
Principal Investigator |
WARABI Yoko Tokyo Metropolitan Organization for Medical Research, 東京都神経科学総合研究所, 研究員 (30399464)
|
|---|
| Project Period (FY) |
2007 – 2009
|
| Project Status |
Completed (Fiscal Year 2009)
|
| Budget Amount *help |
¥5,901,294 (Direct Cost: ¥4,931,765、Indirect Cost: ¥969,529)
Fiscal Year 2009: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2008: ¥2,121,294 (Direct Cost: ¥1,631,765、Indirect Cost: ¥489,529)
Fiscal Year 2007: ¥1,700,000 (Direct Cost: ¥1,700,000)
|
|---|
| Keywords | 多発性硬化症 / インターフェロン / 視神経脊髄炎 / 神経科学 / 免疫学 / 脳神経疾患 / neuromyelitis optica / 二次性進行型 / 抗AQP4抗体 / Foxp3 |
|---|
| Research Abstract |
(1) Secondary progressive multiple sclerosis (SPMS) had a normal function of the regulatory T cells, therefore SPMS had a small number of clonally expanded pathogenic T cells. Neuromyelitis optica expressed results exactly the opposite of SPMS. Japanese multiple sclerosis patients must choice the appropriate therapy according to their classified type.
(2) Early interferon therapy for the Japanese multiple sclerosis patients suppresses the number of relapse and the MRI lesions. Moreover, it effect to sustain the quality of life for the patients.
(3) Because the secondary progressive neuromyelitis optica patients reveal the inflammation and demyelination, they must not be treated with interferon.
|
Report
(4 results)
Research Products
(10 results)
